New BTK Inhibitor Makes Case for Earlier Use in CLL

(MedPage Today) — ORLANDO — Patients with newly diagnosed chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL) lived significantly longer without disease progression when treated with the Bruton’s tyrosine kinase (BTK) inhibitor…

Source link : https://www.medpagetoday.com/meetingcoverage/ashhematology/118905

Author :

Publish date : 2025-12-09 15:30:00

Copyright for syndicated content belongs to the linked Source.

M	T	W	T	F	S	S
1	2	3	4	5	6	7
8	9	10	11	12	13	14
15	16	17	18	19	20	21
22	23	24	25	26	27	28
29	30	31

New BTK Inhibitor Makes Case for Earlier Use in CLL

FDA Probes RSV Drug Safety; Why Some Cancers Shouldn’t Be Treated; New Mpox Strain

Related Posts

FDA Probes RSV Drug Safety; Why Some Cancers Shouldn’t Be Treated; New Mpox Strain

GLP-1s and Cancer: Meta-analysis Shows Little or No Link

Reducing Hospital Readmissions From Nursing Facilities

IL-6 Vaccine Shows Early Benefit in Knee Osteoarthritis

Helping Patients Transition From Pediatrics to Your Practice

Lower Risk Groups Can Cut Back on Cervical Cancer Screening

New BTK Inhibitor Makes Case for Earlier Use in CLL

FDA Probes RSV Drug Safety; Why Some Cancers Shouldn’t Be Treated; New Mpox Strain

GLP-1s and Cancer: Meta-analysis Shows Little or No Link

Reducing Hospital Readmissions From Nursing Facilities

IL-6 Vaccine Shows Early Benefit in Knee Osteoarthritis

Helping Patients Transition From Pediatrics to Your Practice

Lower Risk Groups Can Cut Back on Cervical Cancer Screening

We’ve finally cracked how to make truly random numbers

Categories

Archives